| Literature DB >> 33563974 |
Xiao-Lin Jiang1, Guo-Lin Wang2, Xiang-Na Zhao3, Fei-Hu Yan4, Lin Yao2, Zeng-Qiang Kou1, Sheng-Xiang Ji5, Xiao-Li Zhang5, Cun-Bao Li5, Li-Jun Duan2, Yan Li1, Yu-Wen Zhang1, Qing Duan1, Tie-Cheng Wang4, En-Tao Li4, Xiao Wei3, Qing-Yang Wang6, Xue-Feng Wang4, Wei-Yang Sun4, Yu-Wei Gao4, Dian-Min Kang1, Ji-Yan Zhang7, Mai-Juan Ma8.
Abstract
The dynamics, duration, and nature of immunity produced during SARS-CoV-2 infection are still unclear. Here, we longitudinally measured virus-neutralising antibody, specific antibodies against the spike (S) protein, receptor-binding domain (RBD), and the nucleoprotein (N) of SARS-CoV-2, as well as T cell responses, in 25 SARS-CoV-2-infected patients up to 121 days post-symptom onset (PSO). All patients seroconvert for IgG against N, S, or RBD, as well as IgM against RBD, and produce neutralising antibodies (NAb) by 14 days PSO, with the peak levels attained by 15-30 days PSO. Anti-SARS-CoV-2 IgG and NAb remain detectable and relatively stable 3-4 months PSO, whereas IgM antibody rapidly decay. Approximately 65% of patients have detectable SARS-CoV-2-specific CD4+ or CD8+ T cell responses 3-4 months PSO. Our results thus provide critical evidence that IgG, NAb, and T cell responses persist in the majority of patients for at least 3-4 months after infection.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33563974 PMCID： PMC7873066 DOI： 10.1038/s41467-021-21155-x
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919